The post Aerosmith Charts Another Hit Song — And The Band Has Company appeared on BitcoinEthereumNews.com. Aerosmith and Yungblud’s “Wild Woman” becomes a bestsellerThe post Aerosmith Charts Another Hit Song — And The Band Has Company appeared on BitcoinEthereumNews.com. Aerosmith and Yungblud’s “Wild Woman” becomes a bestseller

Aerosmith Charts Another Hit Song — And The Band Has Company

Aerosmith and Yungblud’s “Wild Woman” becomes a bestseller on multiple charts in the U.K. for the first time, as the joint EP One More Time also returns. UNITED KINGDOM – DECEMBER 07: WEMBLEY ARENA Photo of Steven TYLER and AEROSMITH, Steven Tyler performing live onstage (Photo by Mick Hutson/Redferns)

Redferns

Aerosmith shocked fans all around the world in 2025 by announcing – and within a few weeks, releasing – a collaborative EP with alternative superstar Yungblud. The rock band had previously canceled all live performances due to Steven Tyler’s vocal cord injuries, and it seemed like the band might be finished. After Ozzy Osbourne’s death in July, Aerosmith took part in a tribute to the late rocker at the MTV Video Music Awards. That’s where the group first collaborated with Yungblud, and a special relationship began.

Months after the joint One More Time EP hit No. 1 in the United Kingdom, Aerosmith and Yungblud score a new bestselling song on a pair of tallies with one of the most popular tunes featured on the short project.

“Wild Woman” Becomes a New Hit for Aerosmith and Yungblud

“Wild Woman,” which credits both Aerosmith and Yungblud, debuts on a pair of rosters across the Atlantic. This frame, the cut launches at No. 75 on the Official Singles Downloads chart and breaks onto the Official Singles Sales list, which is not specific to any one format, at No. 85.

Aerosmith Scores Another Career Bestseller

Aerosmith earns a fourth hit on both rankings as “Wild Woman” debuts. The collaborative cut brings the Grammy-winning troupe to a new low point, as it’s the first song from Aerosmith to miss the top 40 on the Official Singles Downloads chart, and one of only two – in addition to “I Don’t Want to Miss a Thing,” which peaked at No. 61 – to land in the lower half of the Official Singles Sales ranking.

Half of Aerosmith’s Bestselling Songs Come from One EP

Half of all of Aerosmith’s career hits on both the Official Singles Sales and Official Singles Downloads charts come from the One More Time EP. In October 2025, lead single “My Only Angel” reached No. 9 on the downloads roster and settled just a few spaces beneath the top 10, at No. 12, on the Official Singles Sales roster.

Yungblud Lands Another Hit in His Home Country

Yungblud, meanwhile, scores his eighteenth career hit on the Official Singles Downloads chart. He’s up to just one more win on the general sales ranking.

Yungblud’s Excellent 2025 Continues Into 2026

MADRID, SPAIN – OCTOBER 11: Yungblud performs onstage during a concert at Palacio Vistalegre Arena on October 11, 2025 in Madrid. (Photo by Mariano Regidor/Redferns)

Redferns

2026 is just beginning, but Yungblud is already off to a fantastic start as “Wild Woman” becomes a bestseller in his home country. The rocker is hoping to score his first Grammy, as he is currently nominated for three honors: Best Rock Performance, Best Rock Song, and Best Rock Album for “Changes,” “Zombie,” and Idols, respectively.

Last year was also a major moment for Yungblud, especially on the U.K. charts. He added more than half a dozen new wins to his totals on the two rosters where “Wild Woman” debuts this time around. That includes a No. 1 with “Changes,” a tribute to Osbourne, which also credits Nuno Bettencourt and Frank Bello. Several solo cuts, such as “Hello Heaven, Hello,” “Lovesick Lullaby,” and the Grammy-nominated “Zombie,” also became powerful sellers, if only for a short time.

One More Time EP Returns as “Wild Woman” Debuts

The current success of “Wild Woman” propels the collaborative One More Time EP back onto the Official Album Downloads chart, where it settles at No. 89. The same collection lifts a single spot to No. 27 on the Official Rock and Metal Albums list, as fans across the U.K. purchase the tune “Wild Woman” in large enough numbers to turn it into a smash.

Source: https://www.forbes.com/sites/hughmcintyre/2026/01/21/aerosmith-charts-another-hit-song—and-the-band-has-company/

Market Opportunity
WilderWorld Logo
WilderWorld Price(WILD)
$0.0547
$0.0547$0.0547
-1.97%
USD
WilderWorld (WILD) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26